Medigene AG: Oral and poster presentations on Medigene's clinical research at ASH conference

Planegg/Martinsried (pta027/05.11.2020/15:05 UTC+1) 5 November 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, is pleased to announce that one oral presentation and one poster presentation will be given at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on 5-8 December 2020. The ASH meeting this year is being held in an all-virtual format due to the continuing COVID-19 pandemic.
The two presentations relate to Medigene's clinical research including detailed results from the dendritic cell (DC) vaccine Phase I/II clinical trial completed earlier this year (presented by the study's Principal Investigator, Dr Yngvar Floisand), as well as preclinical data on the evaluation of PRAME expression and HLA genotype distribution in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Full-length abstracts were published online today at 9:00 am EST (3:00 pm CET).

Oral presentation details:

Title	A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML
Number	166
Authors	Yngvar Floisand, MD, PhD, Iris Bigalke, MD, Dag Josefsen, MD, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Richard Addo, MD, PhD, Dolores J. Schendel, PhD, Kai Pinkernell, MD, Gunnar Kvalheim, MD, PhD
Presenter	Dr. Yngvar Floisand, Department of Cellular Therapy/Hematology, Oslo University Hospital
Session	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML
Session Date	Saturday, 5 December 2020, 12:00 pm - 1:30 pm PT (9:00 pm - 10:30 pm CET)
Presentation Time	12:15 pm PT (9:15 pm CET)

Poster details:

Title	PRAME mRNA Expression in AML/MDS and HLA Genotype Analysis: Impact on Population Coverage and Design of TCR-Based Immunotherapies
Number	2881
Authors	Richard Addo, MD, PhD, Kathrin Davari, PhD, Silke Raffegerst, PhD, Dolores Schendel, PhD, Kai Pinkernell, MD, Simone Thomas, MD
Presenter	Dr. Richard Addo, Medigene
Session	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
Session Date	Monday, 7 December 2020, 7:00 am - 3:30 pm PT (Monday, 7 December 2020, 4:00 pm - Tuesday, 8 December 2020, 12:30 am CET)

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com

About Medigene's DC vaccines
In addition to Medigene's development focus on T cell-receptor modified T cells (TCR-Ts), the Company has developed a new generation of antigen-tailored dendritic cell (DC) vaccines.
Dendritic cells (DC) can take up antigens, process them and present peptides on their surface in a form that can induce antigen-specific T cells to mature and proliferate. In this way, T cells recognize and eliminate tumor cells which bear the same antigen peptide on their surface. Dendritic cells can also induce natural killer cells (NK cells) to attack tumor cells. The scientific team of Medigene has developed new, fast and efficient methods for generating autologous (patient-specific) mature dendritic cells, which have the relevant characteristics to generate very strong T cell and NK cell immune responses. The dendritic cells can be loaded with various tumor antigens to treat different forms of cancer. Since an immune response builds up over the total time of administration of the DC vaccine, this form of therapy is particularly designed for patients who suffer from a tumor disease which has been reduced to such an extent by chemotherapy that the prevention of the recurrence of the tumor disease is the main goal.

About acute myeloid leukemia (AML)
AML is a malignant disease of the hematopoietic system, affecting mainly adults above 60 years of age. In Germany, about 3,600 cases are registered annually.
AML is caused by uncontrolled growth of dysfunctional hematopoietic precursor cells in the bone marrow. These cells prevent the generation of normal blood cells, causing a decrease in erythrocytes and platelets, for example. Typical symptoms of AML include anemia, fever, increased risk of infection, and bleeding. AML progresses rapidly and may be fatal within a few weeks or months, if untreated.
AML treatment is often started with intensive chemotherapy, followed by consolidation with or without allogeneic hematopoietic stem cell transplantation. Unfortunately, a significant proportion of patients suffer a relapse of the original disease. Depending on the biologic risk profile of the disease, age and co-morbidity the long-term survival is highly variable.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene
Dr. Gary Waanders, Dr. Anna Niedl
Phone: +49 89 2000 3333 01
e-mail: investor@medigene.com

LifeSci Advisors
Mary-Ann Chang
Phone: +44 7483 284 853
e-mail: mchang@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)